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Abstract
Background: Noroviruses cause epidemic outbreaks of gastrointestinal illness in all age-groups.
The rapid onset and ease of person-to-person transmission suggest that inhibitors of the initial
steps of virus binding to susceptible cells have value in limiting spread and outbreak persistence.
We previously generated a monoclonal antibody (mAb) 54.6 that blocks binding of recombinant
norovirus-like particles (VLP) to Caco-2 intestinal cells and inhibits VLP-mediated hemagglutination.
In this study, we engineered the antigen binding domains of mAb 54.6 into a single chain variable
fragment (scFv) and tested whether these scFv could function as cell binding inhibitors, similar to
the parent mAb.
Results: The scFv54.6 construct was engineered to encode the light (VL) and heavy (VH) variable
domains of mAb 54.6 separated by a flexible peptide linker, and this recombinant protein was
expressed in Pichia pastoris. Purified scFv54.6 recognized native VLPs by immunoblot, inhibited VLP-
mediated hemagglutination, and blocked VLP binding to H carbohydrate antigen expressed on the
surface of a CHO cell line stably transfected to express α 1,2-fucosyltransferase.
Conclusion:  scFv54.6 retained the functional properties of the parent mAb with respect to
inhibiting norovirus particle interactions with cells. With further engineering into a form deliverable
to the gut mucosa, norovirus neutralizing antibodies represent a prophylactic strategy that would
be valuable in outbreak settings.
Background
Noroviruses are non-enveloped positive strand RNA
viruses that cause foodborne illness worldwide [1]. They
are classified as NIAID Category B priority pathogens
because they are easily transmitted person-to-person and
can cause persistent epidemics. Outbreaks generally occur
in semi-closed community settings including day care
centers, retirement facilities and nursing homes, hospi-
tals, schools, and military training and operations facili-
ties. Large outbreaks on commercial cruise-liners have
been well publicized, and such outbreaks illustrate the
rapid onset epidemic potential of noroviruses and a need
for intervention measures that do not depend on pre-
existing immunity. Recent data suggest the number of out-
breaks attributable to noroviruses may be increasing [2].
The norovirus genome is a 7.7 kilobase RNA comprised of
three open reading frames (ORF) [reviewed in [3]]. ORF1
codes for the nonstructural proteins that are processed co-
and post-translationally by a single viral protease. ORF2
and ORF3 encode structural proteins VP1 and VP2,
respectively, and form the icosahedral capsid. Ninety dim-
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ers of VP1 assemble into virus-like particles (VLPs) when
expressed in insect cells infected with a recombinant bac-
ulovirus [4]. VP1 folds into two major domains termed
the shell (S) and protruding (P) domains [5,6]. The S
domain consists of the N -terminal 280 amino acids and
forms the icosahedron. The P domain is divided into sub-
domains P1 and P2 that participate in dimeric contacts
that increase the stability of the capsid. The P2 domain is
an insertion in the P1 domain and contains a hypervaria-
ble region implicated in receptor binding and immune
reactivity, as well as in interactions with histoblood group
antigens associated with susceptibility to norovirus infec-
tions [7-11].
Therapeutic antibodies have been used successfully in
treatment regimens for diseases including cancer and
rheumatoid arthritis, for transplant rejection, and against
respiratory syncytial virus infections in children [reviewed
in [12]]. Technological advances that include humaniza-
tion to avoid undesirable immunogenicity, and improve-
ments in stability and pharmacokinetics are strategies
employed to improve the clinical utility of antibodies.
Foremost among such strategies is the reduction of anti-
gen binding domains to minimal fragments that retain
reactivity with the targeted antigens [13]. Single chain var-
iable fragments (scFv) are ~27 kDa recombinant proteins
that consist of the light (VL) and heavy (VH) chain variable
regions of a monoclonal antibody (mAb) expressed in a
single construct where they are separated by a flexible pep-
tide linker [14]. Intramolecular folding of the recom-
binant protein results in reconstitution of the antigen
binding domain. These small proteins are relatively easily
produced in high yield in recombinant bacterial or yeast
expression systems [15-17]. Further manipulation and
expression strategies have yielded forms of the scFv mon-
omer where valency is increased by assembly of mul-
timeric forms termed diabodies, triabodies and
tetrabodies [13]. These multimers have been shown to be
more stable and can be engineered to recognize more than
one antigenic target [18,19].
We generated mAb to norovirus VLPs to characterize
domains of VP1 that function in virus binding to cellular
receptors [20]. One mAb (mAb 54.6) to the genogroup I
reference strain Norwalk (NV) blocks binding of recom-
binant VLPs to CaCo-2 intestinal cells and inhibits VLP-
mediated hemagglutination. In the current study, we engi-
neered sequences encoding mAb 54.6 into an scFv to
determine whether functional activity was retained in the
isolated antigen binding domain. The data presented
show the scFv from mAb 54.6 (scFv54.6) was expressed
successfully in Pichia pastoris and retained the antigen
binding and functional activity of the parent mAb. Engi-
neered antibody fragments that block norovirus binding
to cells have potential as an on-site prophylactic strategy
to prevent virus spread and contain epidemics.
Results
VL and VH domains of mAb 54.6 and design of scFv54.6
Anti-rNV mAb 54.6 recognizes non-denatured VP1, inhib-
its VLP-mediated hemagglutination, and blocks VLP bind-
ing to CaCo-2 cells. To determine whether functional
activity of the mAb could be reduced to a smaller antigen
binding domain, sequences encoding the VL and VH genes
of mAb 54.6 were cloned from the hybridoma cells (Fig-
ure 1). A database search for homologies to known
murine V genes was performed with the IgBLAST protocol.
The VL domain of mAb 54.6 is 98.9% identical to VL genes
in the Vκ-23-48 family [21], with the exception of a sub-
stitution of isoleucine for threonine at position 31 in the
Vκ-CDR1. The VH domain was amplified in a single form
highly homologous to the VH7183 gene family [22] and is
96% identical to the VH 50.1 gene. VH genes derived from
the VH7183 family are preferentially used by autoantibod-
ies of various specificities [23]. However, some antibodies
specific for foreign antigens such as galactan and the A/
PR8/34 strain of influenza virus hemagglutinin also are
encoded by VH genes of this family [24,25].
The domain organization of the 245 amino acid scFv54.6
consists of the VL domain at the N terminus separated
from the VH domain at the C terminus by a peptide linker
comprised of the sequence GGKGSGGKGTGGKGSGG-
KGS (Figure 1). The linker composition is a modification
of the peptide linker previously described [26]. C-terminal
myc and histidine tags are expressed in frame with scFv54.6
to allow detection of recombinant protein by immunob-
lot and for downstream purification procedures.
Production of scFv54.6 in P. pastoris and reactivity with rNV 
VP1
The pPICZαA vector contains the methanol-inducible
AOX1 promoter for high level expression in P. pastoris and
the α-factor signal sequence from Saccharomyces cerevisiae
for secretion of recombinant protein into the culture
supernatant [27,28]. During secretion, the signal peptide
is cleaved by the P. pastoris protease KEX2 (kexin), releas-
ing soluble scFv54.6 into the medium. Typical yields fol-
lowing induction of expression with methanol,
purification and concentration, were approximately one
mg of purified scFv54.6 per liter of suspension culture.
scFv54.6 has a calculated molecular mass of approximately
29 kDa. Three closely migrating protein bands were
detected by silver stain (Figure 2A). The top two bands
strongly reacted with the anti c-myc mAb under both
reducing and non-reducing conditions (Figure 2B). The
exact composition of the two bands is not clear, but they
likely are products of slightly different KEX protease cleav-
age sites at the N terminus of the protein, because the mycVirology Journal 2008, 5:21 http://www.virologyj.com/content/5/1/21
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epitope tag recognized by the antibody resides at the C ter-
minus. In support of this interpretation, N-terminal
amino acid sequence analysis of three forms of recom-
binant protein rhIFN-λ1 showed proteolytic processing
adjacent to and outside of the KEX2 cleavage site [29].
Recognition of rNV VP1 by mAb 54.6 is conformation
dependent because this antibody reacts in immunoblots
only when VP1 has not been denatured by boiling in SDS
and β-mercaptoethanol [20]. scFv54.6 was tested for the
ability to bind rNV VP1 in immunoblots to determine
whether the fragment retained reactivity of the parent
mAb. Immunoblots were probed with scFv54.6 and bind-
ing to rNV VP1 was detected with anti-c-myc mAb and
goat anti-mouse secondary antibody. Similar to mAb
54.6, scFv54.6 recognized VP1 only under non-denaturing,
non-reducing conditions (Figure 3). Neither the mAb
54.6 nor scFv54.6 recognized denatured VP1.
scFv54.6 blocks rNV VLP-mediated hemagglutination
Norovirus VLPs agglutinate red blood cells in a type-spe-
cific manner [30] and mAb 54.6 inhibits this activity for
rNV VLPs [20]. To determine whether scFv54.6 inhibited
hemagglutination, rNV VLPs were mixed with type O rbc
in the presence or absence of scFv54.6 or mAb 54.6. Figure
4A shows that scFv54.6  successfully blocked rNV VLP-
mediated hemagglutination in a dose-dependent manner.
The lowest inhibitory concentration was 3.0 μg and 0.375
μg of scFv54.6 and the parent mAb, respectively (Figures 4A
Expression of scFv54.6 in P. pastoris Figure 2
Expression of scFv54.6 in P. pastoris. (A) SDS-PAGE analysis of 
affinity chromatography purified scFv54.6 after 72 hrs induc-
tion. (B) Purified scFv54.6 electrophoresed under non-reduc-
ing (NR) and reducing (R) conditions was probed with anti-c-
myc mAb and HRP-conjugated goat anti-mouse IgG.
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Amino acid sequence and domain organization of scFv54.6 Figure 1
Amino acid sequence and domain organization of scFv54.6. VL (red) and VH (blue) chains are shown as a single sequence joined 
together with a 20 amino acid linker (shaded). Complementarity determining regions (CDRs) of VL and VH are underlined. 
Amino acid numbering is according to Kabat [43].
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and 4B), yielding an HI titer for scFv54.6 eight-fold lower
than that of mAb 54.6. While it is possible that part of the
difference in HI titer can be attributed to slight differences
in concentration, it is likely that the lower HI titer of
scFv54.6 reflects the monovalent binding activity of the
fragment.
scFv54.6 blocks binding of rNV VLPs to CHO-FTBKE cells
CHO cells do not express ABH histoblood group antigens,
but CHO cells stably transfected with the rat FTB gene
encoding α 1,2-FT confers the ability to bind rNV VLPs to
these cells [31]. scFv54.6 was tested for the ability to block
binding of rNV VLPs to CHO-FTBKE cells. In the absence of
antibody, 48.2% of cells bound VLPs (Figure 5). When
VLPs were pre-incubated with scFv54.6, the percentage of
positive cells was reduced to 10.2%. No reduction in
binding was observed with samples from non-expressing
X33 culture subjected to the same purification procedure
as the scFv54.6  (see Figure 2A). These results suggest
scFv54.6 is able to block binding of rNV VLPs to H type
antigen on the cell surface.
Discussion
Immunity to noroviruses is complex and the correlates of
protection from re-infection are unclear. Short-term
immunity can be induced by prior infection, but long-
lasting immunity apparently is more difficult to achieve.
Gastroenteritis caused by norovirus generally is a self-lim-
iting disease. However, the ease in which noroviruses are
transferred by person-to-person spread suggest inhibitors
designed to interfere with the initial steps of virus infec-
tion could reduce the duration of illness, shedding of
infectious virus, and the number of susceptible individu-
als in a population. This issue is particularly relevant in
semi-closed communities including nursing homes and
daycare centers, where age may affect the efficacy of vac-
cines. We envision that inhibitors will be easily adminis-
tered on-site as necessary and will by design, be
independent of an adaptive immune response.
P. pastoris was chosen for scFv54.6 expression because of
reported high protein yield, low levels of glycosylation,
simplicity of the culture medium and protein solubility.
Numerous scFvs have been produced in P. pastoris with
variable yields ranging from 0.4 to 20 mg/L [26,32,33].
We have shown that scFv54.6 expressed in P. pastoris at
yields of ~1.0 mg/L retain the inhibitory functions of the
parent mAb, suggesting humanized derivatives of these
fragments could prove useful for development of anti-
norovirus prophylactics.
Antibodies have received significant interest as biophar-
maceuticals. At least 18 mAb are in use in humans and >
100 are in clinical trials as therapeutics for treatment of
cancer and chronic inflammatory diseases, and for pre-
vention of transplant organ rejection [12]. Likewise, engi-
neered smaller domains consisting of the functional
antigen binding domains are viable alternatives to the
costs associated with humanization and production of
Dose-dependent hemagglutination inhibition by recombinant  scFv54.6 Figure 4
Dose-dependent hemagglutination inhibition by recombinant 
scFv54.6. Numbers above the wells indicate the amount of 
antibody in the reactions in μg. (A) scFv54.6 (B) mAb 54.6 (C) 
PBS-H and rbc only. (+) indicates presence of rNV particles, 
(-) indicates absence of rNV particles.
24      12      6       3      1.5    0.75     0
6        3      1.5    0.75  0.37  0.18   0
+
-
+
-
+
-
A
B
C
Western blot analysis of rNV VP1 probed with (A) mAb 54.6  and (B) scFv54.6 under non-denaturing (left panel) and dena- turing (right panel) conditions Figure 3
Western blot analysis of rNV VP1 probed with (A) mAb 54.6 
and (B) scFv54.6 under non-denaturing (left panel) and dena-
turing (right panel) conditions.
Not boiled
Boiled 
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Boiled 
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mAb in mammalian cell culture systems [13]. Monova-
lent scFv are easily produced in high yield in recombinant
bacterial or yeast expression systems, and when secreted
into the medium, are readily purified to homogeneity by
scalable purification procedures. scFv also can be
designed to be bispecific, or engineered to preferentially
form multimers including diabodies, triabodies, and
tetrabodies that increase valency [13]. These multivalent
properties with consequent increased avidity are particu-
larly relevant for prophylaxis of viral diseases because,
similar to other cellular receptor-ligand interactions, viral
attachment proteins engage multiple copies of receptors
on the cell surface.
Several examples of antibody fragments capable of neu-
tralizing virus infection both in vitro and in vivo have
been reported. For example, fragments selected from a
human scFv library for reactivity with the West Nile virus
envelope protein protected mice against lethal virus chal-
lenge when administered both prior to or shortly after
infection [34]. Recombinant virus-specific scFv efficiently
neutralized human papillomavirus infection in culture
[35]. Affinity-selected scFv against hepatitis B virus also
neutralized infection in vitro [36], and purified scFv that
recognize intercellular adhesion molecule ICAM-1 effec-
tively blocked transmission of HIV across an epithelial cell
monolayer both in vitro and in a small animal model
[37]. Together, these data illustrate the utility of scFv as a
viable way to provide passive immunity to viral infec-
tions.
Our studies were approached with the idea that engi-
neered antibody fragments could provide a rapidly deliv-
erable substance for protection against norovirus
infection where the potential for epidemics is heightened
in semi-closed community settings. However, successful
delivery of soluble proteins, including scFv, to the gut is
unlikely because of potential instability from exposure to
gut proteases. Recently, pathogen-specific scFv expressed
on the surface of probiotic lactobacilli provided protec-
tion in small animal models of enteric viral infection [38].
This or a similar system that is amenable to oral adminis-
tration could provide scaffolding for stable presentation
of norovirus neutralizing scFv to the gut.
The antigenic specificity in the norovirus capsid lies pri-
marily in the hypervariable P2 domain of VP1, and ide-
ally, antibody fragments would be reactive with multiple
strains. Genogroup II.4 strains currently are the predomi-
nant strains circulating worldwide, but others also have
been reported [2,39-42]. In the absence of broadly cross-
reactive antibodies, the ability to manipulate scFv frag-
ments into bispecific molecules suggests these neutraliz-
ing fragments can be engineered to cover a combination
scFv54.6 blocks the binding of rNV VLPs to CHO-FTBKE cells Figure 5
scFv54.6 blocks the binding of rNV VLPs to CHO-FTBKE cells. 
rNV VLPs were incubated with CHO-FTBKE cells in the pres-
ence or absence of scFv54.6 and sorted by flow cytometry (A) 
VLP binding detected by incubation with scFv54.6 followed by 
anti-c-myc mAb and PE-conjugated goat anti-mouse antibody. 
(B) VLP binding detected by incubation with anti rNV MAb 
72.1 PE-conjugated goat anti-mouse and C) scFv54.6 were 
pre-incubated with VLPs for one hour prior to addition to 
the cells. Bound VLPs were detected by MAb 72.1.
A
B
C
27.8%
10.2%
48.2% Virology Journal 2008, 5:21 http://www.virologyj.com/content/5/1/21
Page 6 of 8
(page number not for citation purposes)
of antigenic types within a single delivery system. Con-
struction of such bispecific fragments is underway.
Material and methods
Cloning of variable domain genes
Total RNA was isolated from hybridoma 54.6 [20] with
the RNeasy Mini kit (Qiagen). Reverse transcription (RT)
was conducted with 5 μg of total RNA using M-MLV RT
(Invitrogen) and 3' oligonucleotides MVK-R and MVH-R
(Table 1) for first-strand synthesis of cDNA corresponding
to the variable regions of the light and heavy chains, VL
and VH, respectively. Two μl of the cDNA reaction were
used in PCR reactions conducted with degenerate 5' oligo-
nucleotides for leader sequences (Table 1) and the 3' oli-
gonucleotides used in the RT reaction. A single PCR
amplicon obtained in each reaction was cloned into the
pCR2.1 TOPO vector (Invitrogen), and sequenced using
M13 reverse and M13 forward (-20) primers. The VL and
VH sequences then were amplified from the pTOPO clones
using the oligonucleotides described in Table 2. Both VL
and VH PCR products were digested with Kpn I and ligated
with T4 DNA ligase. The ligation products were used as
templates to amplify the joined VL and VH regions sepa-
rated by a 60 bp linker. The resulting PCR products then
were cloned into the Pichia pastoris expression vector
pPICZαA (Invitrogen) utilizing the EcoR I and  Xba I
restriction sites to yield pPICZαA-scFv54.6. Colonies were
selected on zeocin-containing low salt agar plates contain-
ing 1% tryptone, 0.5% yeast extract, 0.5% sodium chlo-
ride and 25 μg/ml zeocin.
Transformation of P. pastoris X33 and selection of 
recombinants
P. pastoris strain X33 was transformed with 10 μg of Pme I-
linearized pPICZαA-scFv54.6  following the Easyselect
Pichia expression protocol (Invitrogen). In brief, electro-
competent cells were prepared from 200 ml of YPD
medium inoculated with a fresh culture of P. pastoris X33
and incubated at 29°C, shaking at 250 rpm until the
OD600 nm reached 1.3. The cells then were harvested by
centrifugation for five minutes at 1,500 × g, washed twice
with sterile ice-cold water and once with 10 ml of ice-cold
1 M sorbitol, and then suspended in 0.5 ml of 1 M sorbi-
tol. Electroporation was conducted by mixing 80 μl of this
cell suspension with 10 μg of linearized pPICZαA-scFv54.6
in a 0.2-cm cuvette. The cells were pulsed with 1.5 kV at a
resistance setting of 129 ohms using a BTX ECM 630 elec-
troporator. One ml of 1.0 M sorbitol was immediately
added to the pulsed cells which then were transferred to a
15 ml tube and incubated for two hours at 29°C. Cells
were plated onto YPD agar supplemented with 1.0 M
sorbitol and containing 100 μg/ml of zeocin. Colonies
were screened for multi-copy recombinants by patching
onto YPD agar plates containing concentrations of zeocin
ranging from 100 to 2,000 μg/ml. Recombinants selected
on 2,000 μg/ml zeocin were screened for Met+ phenotype
by streaking onto minimal methanol agar medium and
inserts were confirmed by PCR.
scFv expression and purification
scFv54.6  expression was conducted by growing recom-
binants in 50 ml buffered complex glycerol medium
(BGMY, pH 6.0) for 18 hrs at 29°C. Cells cultured to log
phase were harvested by centrifugation at 1,500 × g,
diluted to an OD600 nm of 1.0 in buffered complex metha-
nol medium (BMMY, pH 6.0) to induce expression, and
then incubated for 72 hrs at 25°C in a shaking incubator
at 250 rpm. At each 24 hour time point, 100% methanol
was added to a final concentration of 1.0%. Casamino
acids were added to BMMY to a final concentration of
1.0% to reduce proteolysis. One ml samples were taken at
selected time points and supernatants were analyzed for
scFv54.6 expression by SDS-PAGE and immunoblotting
using anti-c-myc (Clontech) as the primary antibody.
The pre-cleared supernatant from induced cultures was
precipitated by addition of ammonium sulfate to 45% sat-
uration and incubated overnight at 4°C. Proteins were
harvested by centrifugation for 25 minutes at 6,700 × g
and then dialyzed against sodium phosphate saline buffer
Table 1: Degenerate oligonucleotides for PCR amplification of VL and VH of mAb 54.6
MVH-R 5'- GAC HGA TGG GGS TGT YGT GCT AGC TGN RGA GAC DGT GA -3'
MVK-R 5'- GGA TAC AGT TGG TGC AGT CGA CTT ACG TTT KAT TTC CAR CTT -3'
VK1-F 5'- GGG GAT ATC CAC CAT GGA GAC AGA CAC ACT CCT GCT AT -3'
VK2-F 5'- GGG GAT ATC CAC CAT GGA TTT TCA AGT GCA GAT TTT CAG -3'
VK3-F 5'- GGG GAT ATC CAC CAT GGA GWC ACA KWC TCA GGT CTT TRT A -3'
VK4-F 5'- GGG GAT ATC CAC CAT GKC CCC WRC TCA GYT YCT KGT -3'
VK5-F 5'- GGG GAT ATC CAC CAT GAA GTT GCC TGT TAG GCT GTT G -3'
VH1-F 5'- GGG GAT ATC CAC CAT GGR ATG SAG CTG KGT MAT SCT CTT -3'
VH2-F 5'- GGG GAT ATC CAC CAT GRA CTT CGG GYT GAG CTK GGT TTT -3'
VH3-F 5'- GGG GAT ATC CAC CAT GGC TGT CTT GGG GCT GCT CTT CT -3'
VH4-F 5'- GGG GAT ATC CAC CAT GAT RGT GTT RAG TCT TYT GTR CCT G -3'Virology Journal 2008, 5:21 http://www.virologyj.com/content/5/1/21
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(50 mM monobasic sodium phosphate, 150 mM NaCl,
pH 7.4). The dialysate was diluted with an equal volume
of Ni-NTA buffer (50 mM monobasic sodium phosphate,
300 mM NaCl, pH 8.0) containing 25 mM imidazole and
then incubated with Ni-NTA beads for 20 minutes at 4°C
with end-over-end rotation. Beads were collected by cen-
trifugation for two minutes at 800 × g and then washed
five times with wash buffer (50 mM monobasic sodium
phosphate, 300 mM NaCl, 20 mM imidazole, pH 8.0).
His-tagged proteins were eluted with Ni-NTA buffer con-
taining 250 mM imidazole, dialyzed against sodium
phosphate buffer, pH 6.5, and concentrated by ultrafiltra-
tion through a Centricon Plus-20 column (Millipore).
Hemagglutination inhibition assay (HI)
The HI assay was performed as described previously [20].
In brief, 50 μl serial dilutions of purified scFv54.6 or mAb
54.6 in sterile PBS-H (0.01 M sodium phosphate, 0.15 M
sodium chloride, pH 5.5) were added to the wells of a
vinyl flexible V-bottom 96-well plate (Costar), followed
by addition of 50 μl of a 0.5 % suspension of type O red
blood cells. Ten μl of VLPs (5 ng/ml in PBS-H) or PBS-H
were added to the appropriate wells indicated in the figure
legend. The plate was gently agitated and incubated for
two hours at 4°C.
Construction of CHO-FTBKE cells and VLP blocking assays
A stable Chinese Hamster Ovary (CHO) cell line that
expresses  α 1,2-fucosyltransferase (α 1,2-FT) was con-
structed as previously described [31]. The rat FTB gene
encoding α 1,2-FT was amplified by RT-PCR from total
RNA isolated from rat colon using oligonucleotides FTB-F
(5' CAAGGATCCATGGCCAGCGCCCAGGTT-3') and
FTB-R (5' CACCTCGAGTTAGTGCTTAAGGAGT-
GGGGAC-3'). The PCR amplicon was cloned in BamHI
and XhoI sites of pcDNA3.1/Myc-His(+)A vector (Clon-
tech). CHO-K1 cells were transfected with the FTB cDNA
and stably maintained in RPMI containing 0.4 mg/ml
G418. Expression of α 1,2-FT was confirmed by binding
of FITC-conjugated UEA-lectin as previously described
[31].
The ability of scFv54.6 to block binding of VLPs to cells was
measured by flow cytometry using R-Phycoerythrin (PE)-
conjugated anti-mouse IgG (Jackson Immunoresearch
Laboratories). Binding assays were performed as
described previously [31]. Briefly, 990 ng of VLPs diluted
in PBS (pH 6.7) containing 0.1% gelatin were incubated
for two hours at 4°C in the presence or in the absence of
scFv54.6 (5 μg/ml) or control IgG Fab fragment (Jackson
Immunoresearch Labs). The reactions were mixed with 2
× 105 CHO-FTBKE cells and incubated for another two
hours. Cells were washed and VLP binding was detected
by incubation for one hour with anti-rNV mAb 72.1 [20]
followed by a 45 minute incubation with PE-conjugated
goat anti-mouse antibody at a final concentration of 2.0
μg/ml. MAb 72.1 recognizes rNV particles but is different
from mAb 54.6, as their VL and VH sequences are not iden-
tical (unpublished data). Fluorescent cells were counted
on a FACSCalibur (Becton Dickinson) and the data were
analyzed with CellQuest Pro software (version 5.2.1; BD
Biosciences).
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